- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07267793
Pitkäaikainen tutkimus CartiPRO:sta polven kivun hoitoon nivelrikon tai rustovaurion vuoksi
CartiPRO-injektion pitkäaikainen teho ja turvallisuus polvikivun lievittämisessä osteoartriittia ja/tai erilaisia rustovaurioita sairastavilla potilailla: monikeskuksellinen, yksisokkainen, satunnaistettu, ei-heikommuutta tutkiva, sponsorin aloittama tutkimus
This clinical trial aims to evaluate and compare the efficacy and safety of CartiPRO, an approved intra-articular atelocollagen injection, versus Synovian injection for the relief of knee pain in patients with knee osteoarthritis. The investigational device is administered intra-articularly, with a second injection given 24 weeks after the first dose. Primary and secondary endpoints include changes in pain scores (VAS), functional assessments (WOMAC, SF-36), and safety evaluations over a 36-week period.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
Yksityiskohtainen kuvaus
Knee osteoarthritis (OA) is the most common joint disorder, primarily caused by the destruction of articular cartilage. Symptoms typically include joint pain, stiffness, and muscle contraction. According to the World Health Organization, in 2013, an estimated 10-15% of adults over the age of 60 were affected by OA, significantly impacting their quality of life.
Collagen degradation is a key feature of cartilage damage in OA. Collagen-based injectable materials, such as atelocollagen, are being explored as potential therapeutic options to restore collagen and improve clinical outcomes. Unlike other injectable substances like hyaluronic acid or corticosteroids, collagen's stable triple helix structure and long half-life make it more resistant to enzymatic degradation, offering a potentially longer-lasting effect.
Despite this, long-term and repeated use data for atelocollagen injections in knee OA are limited both domestically and internationally. This study aims to provide robust clinical evidence on the efficacy and safety of repeated intra-articular atelocollagen injections for knee pain relief in patients with knee OA.
This is a randomized, single-blind, active-controlled study comparing CartiPRO with Synovian. Subjects with knee OA and symptomatic knee pain will receive the investigational device intra-articularly. A second dose will be administered at 24 weeks. The primary outcome is the change in 100-mm weight-bearing pain (WBP) VAS score at 12 weeks compared to baseline.
Secondary outcomes include VAS changes in WBP, resting pain (RP), motion pain (MP), and night pain (NP) at multiple time points, as well as changes in WOMAC and SF-36 scores. Long-term efficacy will be assessed after re-injection. Safety assessments include adverse events, local reactions, physical examination, vital signs, and laboratory tests.
Study Visits:
Visit 1: Screening Visit 2: First injection (baseline) Visit 3: 2 weeks after injection Visit 4: 4 weeks after injection Visit 5: 12 weeks after injection Visit 6: 24 weeks after injection (second dose) Visit 7: 36 weeks after first injection
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Bundang-gu
-
Seongnam-si, Bundang-gu, Etelä -Korea, 13620
- Seoul National University Bundang Hospital
-
Seoul, Bundang-gu, Etelä -Korea, 13496
- CHA Bundang Medical Center
-
-
Eunpyeong-gu
-
Seoul, Eunpyeong-gu, Etelä -Korea, 03312
- The Catholic University of Korea Eunpyeong St. Mary's Hospital
-
-
Namdong-gu
-
Seoul, Namdong-gu, Etelä -Korea, 21565
- Gachon University Gil Hospital
-
-
Seochogu
-
Seoul, Seochogu, Etelä -Korea, 06591
- The Catholic University of Korea Seoul St. Mary's Hospital
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria
-
Age 19 years and older
-
Diagnosed with unilateral or bilateral knee osteoarthritis according to American College of Rheumatology (ACR) criteria, with at least 3 of the following 6 features:
- Age ≥50 years
- Morning stiffness <30 minutes
- Crepitus on active motion
- Bony tenderness
- Bony enlargement
- No palpable warmth
-
Radiographic evidence of Kellgren-Lawrence grade I, II, or III osteoarthritis within 6 months prior to screening or at screening visit
-
Weight-bearing pain Visual Analogue Scale (VAS) score ≥40 mm in at least one knee joint at screening
-
Able to walk without assistive devices (walkers or canes), OR if using a walking aid routinely for past 6 months, able to continue using the same device throughout the study
-
Able to understand and complete efficacy assessment questionnaires
-
Willing and able to provide written informed consent
Exclusion Criteria
- Body Mass Index (BMI) ≥32 kg/m²
- Chronic inflammatory joint disease (e.g., rheumatoid arthritis)
- Inflammatory joint disease (e.g., septic arthritis)
- Secondary knee osteoarthritis due to ochronosis, hemochromatosis, or systemic disease
- Painful musculoskeletal conditions (e.g., Sudeck's atrophy, Paget's disease, herniated intervertebral disc)
- Polyarticular disease with severe osteoarthritis in other joints (e.g., hip) that may affect knee pain evaluation
- Radiographic evidence of definite loss of patellofemoral joint space
- Moderate to severe joint effusion confirmed by positive patellar tap test or equivalent
- History of myocardial infarction, congestive heart failure, other serious cardiac disease, or uncontrolled hypertension (≥140/90 mmHg despite treatment with ≥3 antihypertensive agents)
- History of autoimmune disease
- Active infection requiring parenteral antibiotics
- History of psychiatric disorder or epilepsy
- Cancer diagnosis within 5 years prior to screening
- Uncontrolled type 1 or type 2 diabetes mellitus (HbA1c >7%)
- Surgical procedures (including arthroscopy) on target knee within 1 year (surgery on contralateral knee or hip may be exclusionary if it could affect target knee assessment)
- Intra-articular corticosteroid injection into target knee within 12 weeks
- Systemic corticosteroid use within 4 weeks (topical and inhaled corticosteroids permitted)
- Surgery or radiation therapy to knee joint within 12 weeks, or not fully recovered from side effects
- Immunosuppressive therapy (e.g., Cyclosporine A, Azathioprine) within 6 weeks
- Intra-articular injections (e.g., hyaluronic acid) into knee joint within 6 months
- Prohibited concomitant medications within 2 weeks (unless washout period is adequate)
- Anticoagulants (e.g., warfarin, NOACs), antiplatelet agents (e.g., aspirin >100 mg/day, clopidogrel; low-dose aspirin ≤100 mg/day permitted), thrombolytic agents (e.g., urokinase, alteplase), or Vitamin E >1000 IU/day within 2 weeks (unless adequate washout)
- Habitual use (≥3 months) of psychoactive drugs or narcotic analgesics that may affect pain perception
- History of cell therapy or gene therapy to target joint
- Planned cell therapy or gene therapy to target joint
- Abnormal laboratory values at screening:
- ALT, AST, BUN, or serum creatinine >2× upper limit of normal
- Engaged in high-intensity aerobic or heavy anaerobic exercise that may affect the knee joint
- Dermatological disease at injection site or site deemed unsuitable for injection
- Ligament instability of Grade II or higher in target knee (Grade 0: none; Grade I: 0-5 mm; Grade II: 5-10 mm; Grade III: >10 mm)
- Known hypersensitivity to investigational product or its components
- Pregnant or breastfeeding women
- Women or men of childbearing potential unwilling to use acceptable contraception during study (acceptable methods: intrauterine device, tubal ligation, sterilization surgery, condom or diaphragm with spermicide, natural family planning)
- Participation in another clinical trial within 4 weeks
- Cognitive impairment or dementia preventing informed consent
- Any other condition that makes the subject unsuitable for study participation per investigator judgment
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Tukevaa hoitoa
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kaksinkertainen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Study Group
Group applied with CartiPRO |
Clinical subjects are enrolled after the investigator confirms eligibility, and subjects in the study group receive treatment Dalim Tissen's CartiPRO. Intra-articular medical device injection at baseline and Week 12; final assessment at Week 36. |
|
Active Comparator: Control group
Group applied with Synovian® |
Clinical subjects are enrolled after the investigator confirms eligibility, and subjects in the study group receive treatment Synovian®. Intra-articular medical device injection at baseline and Week 12; final assessment at Week 36. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change from baseline in 100-mm Weight-Bearing Pain (WBP) Visual Analogue Scale (VAS) score (0-100 mm)
Aikaikkuna: at week 12 after the first administration
|
The change from baseline in Weight-Bearing Pain will be assessed using a 100-mm visual analogue scale ranging from 0 mm, no pain, to 100 mm, worst imaginable pain. Higher scores indicate more severe pain. |
at week 12 after the first administration
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change from Baseline in Weight-Bearing Pain Visual Analogue Scale Score (0-100 mm)
Aikaikkuna: at Weeks 2, 4, and 24 after the first administration
|
The change from baseline in Weight-Bearing Pain will be assessed using a 100-mm visual analogue scale ranging from 0 mm, no pain, to 100 mm, worst imaginable pain. Higher scores indicate more severe pain. |
at Weeks 2, 4, and 24 after the first administration
|
|
Change from Baseline in Western Ontario and McMaster Universities Osteoarthritis Index Total and Subscale Scores
Aikaikkuna: at Weeks 2, 4, 12, and 24 after the first administration
|
The change from baseline in the Western Ontario and McMaster Universities Osteoarthritis Index will be assessed for the pain, stiffness, and physical function subscales, as well as the total score. Each item is rated from 0 to 4, where 0 indicates no symptoms and 4 indicates extreme symptoms. Subscale scores are calculated by summing item scores, and the total score is calculated as the sum of the subscale scores. Higher scores indicate worse symptoms and poorer function. |
at Weeks 2, 4, 12, and 24 after the first administration
|
|
Change from Baseline in 36-Item Short Form Health Survey Domain Scores (SF-36)
Aikaikkuna: at Weeks 2, 4, 12, and 24 after the first administration
|
The change from baseline in the 36-Item Short Form Health Survey (SF-36) will be assessed using the eight domain scores: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. Each domain score ranges from 0 to 100, where higher scores indicate better health status/quality of life. |
at Weeks 2, 4, 12, and 24 after the first administration
|
|
Change from Baseline in Rest Pain Visual Analogue Scale Score (0-100 mm)
Aikaikkuna: at Weeks 2, 4, 12, and 24 after the first administration
|
The change from baseline in Rest Pain will be assessed using a 100-mm visual analogue scale ranging from 0 mm, no pain, to 100 mm, worst imaginable pain. Higher scores indicate worse pain. |
at Weeks 2, 4, 12, and 24 after the first administration
|
|
Change from Baseline in Motion Pain Visual Analogue Scale Score (0-100 mm)
Aikaikkuna: at Weeks 2, 4, 12, and 24 after the first administration
|
The change from baseline in Motion Pain will be assessed using a 100-mm visual analogue scale ranging from 0 mm, no pain, to 100 mm, worst imaginable pain. Higher scores indicate more severe pain. |
at Weeks 2, 4, 12, and 24 after the first administration
|
|
Change from Baseline in Night Pain Visual Analogue Scale Score (0-100 mm)
Aikaikkuna: at Weeks 2, 4, 12, and 24 after the first administration
|
The change from baseline in Night Pain will be assessed using a 100-mm visual analogue scale ranging from 0 mm, no pain, to 100 mm, worst imaginable pain. Higher scores indicate more severe pain. |
at Weeks 2, 4, 12, and 24 after the first administration
|
|
Change from Week 24 (Re-administration) in Weight-Bearing Pain Visual Analogue Scale Score (0-100 mm)
Aikaikkuna: at Week 36 (12 weeks after re-administration)
|
The change from Week 24, defined as the time of re-administration, in Weight-Bearing Pain will be assessed using a 100-mm visual analogue scale ranging from 0 mm, no pain, to 100 mm, worst imaginable pain.Higher scores indicate worse pain. |
at Week 36 (12 weeks after re-administration)
|
|
Change from Week 24 (Re-administration) in Rest Pain Visual Analogue Scale Score (0-100 mm)
Aikaikkuna: at Week 36 (12 weeks after re-administration)
|
The change from Week 24, defined as the time of re-administration, in Rest Pain will be assessed using a 100-mm visual analogue scale ranging from 0 mm, no pain, to 100 mm, worst imaginable pain.Higher scores indicate worse pain. |
at Week 36 (12 weeks after re-administration)
|
|
Change from Week 24 (Re-administration) in Motion Pain Visual Analogue Scale Score (0-100 mm)
Aikaikkuna: at Week 36 (12 weeks after re-administration)
|
The change from Week 24, defined as the time of re-administration, in Motion Pain will be assessed using a 100-mm visual analogue scale ranging from 0 mm, no pain, to 100 mm, worst imaginable pain. Higher scores indicate more severe pain. |
at Week 36 (12 weeks after re-administration)
|
|
Change from Week 24 (Re-administration) in Night Pain Visual Analogue Scale Score (0-100 mm)
Aikaikkuna: at Week 36 (12 weeks after re-administration)
|
The change from Week 24, defined as the time of re-administration, in Night Pain will be assessed using a 100-mm visual analogue scale ranging from 0 mm, no pain, to 100 mm, worst imaginable pain. Higher scores indicate more severe pain. |
at Week 36 (12 weeks after re-administration)
|
|
Change from Week 24 (Re-administration) in Western Ontario and McMaster Universities Osteoarthritis Index Total and Subscale Scores
Aikaikkuna: at Week 36 (12 weeks after re-administration)
|
The change from Week 24, defined as the time of re-administration, in the Western Ontario and McMaster Universities Osteoarthritis Index will be assessed for the pain, stiffness, and physical function subscales, as well as the total score. Each item is rated from 0 to 4, where 0 indicates no symptoms and 4 indicates extreme symptoms. Subscale scores are calculated by summing item scores, and the total score is calculated as the sum of the subscale scores. Higher scores indicate worse symptoms and poorer function. |
at Week 36 (12 weeks after re-administration)
|
|
Change from Week 24 (Re-administration) in 36-Item Short Form Health Survey Domain Scores (SF-36)
Aikaikkuna: at Week 36 (12 weeks after re-administration)
|
The change from Week 24, defined as the time of re-administration, in the 36-Item Short Form Health Survey (SF-36) will be assessed using the eight domain scores: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. Each domain score ranges from 0 to 100. Higher scores indicate better health status/quality of life. |
at Week 36 (12 weeks after re-administration)
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: Yong In, Ph.D, The Catholic University of Korea
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- DLTS_05
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Undecided. The plan for sharing individual participant data has not yet been determined.
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .